Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ISA 101

Drug Profile

ISA 101

Alternative Names: HPV-16; HPV-SLP; HPV16-SLP; Human papilloma virus type 16 E6/E7 synthetic long peptides - ISA Pharmaceuticals; ISA 101b; ISA-101; ISA-HPV; ISA-HPV-01; ISA-HPV-SLP®; SLP-HPV-01

Latest Information Update: 15 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ISA Pharmaceuticals
  • Developer Bristol-Myers Squibb; ISA Pharmaceuticals; Regeneron Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cervical cancer; Vulvar intraepithelial neoplasia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical cancer; Head and neck cancer; Oropharyngeal cancer; Solid tumours; Squamous cell cancer; Vulvar intraepithelial neoplasia
  • Phase I/II Anal intraepithelial neoplasia

Most Recent Events

  • 12 Dec 2023 Efficacy and adverse events data from a phase II trial in Oropharyngeal cancer was released by ISA Pharmaceuticals
  • 12 Dec 2023 ISA Pharmaceuticals plans a confirmatory phase III trial for Oropharyngeal cancer
  • 06 Jun 2023 Efficacy and adverse events data from a phase II trial in Squamous cell cancer released by ISA Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top